Peer support boosted Hepatitis C treatment access among marginalised populations in England: A Bayesian causal factor analysis

Constantin Schmidt(MRC Biostatistics Unit), Daniela De Angelis(MRC Biostatistics Unit), Stuart Smith(The Hepatitis C Trust), Leila Reid(The Hepatitis C Trust), Pantelis Samartsidis(MRC Biostatistics Unit), Shaun Seaman(MRC Biostatistics Unit), Graham Foster(Queen Mary University of London), Beatrice Emmanouil(Queen Mary University of London)

medRxiv

April 22, 2026

10.64898/2026.04.20.26351261

Cited by 0

Related Papers

Global Variations in Heart Failure Etiology, Management, and Outcomes

|JAMA|2023|164

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)

|BMJ Open|2019|57

Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine.

|PubMed|1985|47

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England

|Addiction|2019|44

ROBIN: A unified nanopore-based assay integrating intraoperative methylome classification and next-day comprehensive profiling for ultra-rapid tumor diagnosis

|Neuro-Oncology|2025|21